Capricor preps phase 3 for Duchenne cell therapy as it seeks a partnerCapricor Therapeutics’ bid to find a partner for its Duchenne muscular dystrophy (DMD) cell therapy CAP-1002 could get Share XCapricor preps phase 3 for Duchenne cell therapy as it seeks a partnerhttps://pharmaphorum.com/news/capricor-preps-phase-3-for-duchenne-cell-therapy-as-it-seeks-a-partner/
Roche joins others in dropping myostatin inhibitor for DMDThe prospects of a new class of Duchenne muscular dystrophy therapies have taken another downturn after Roche abandoned Share XRoche joins others in dropping myostatin inhibitor for DMDhttps://pharmaphorum.com/news/roche-joins-others-in-dropping-myostatin-inhibitor-for-dmd/
Allergan gets FDA okay for paediatric Botox useThe FDA has approved Allergan’s Botox to treat lower-limb spasticity in children, further extending the use of the Share XAllergan gets FDA okay for paediatric Botox usehttps://pharmaphorum.com/news/allergan-gets-fda-okay-for-paediatric-botox-use/
NS Pharma steals a march on Sarepta with DMD drugJapan’s Nippon Shinyaku Pharma has filed for approval of its Duchenne muscular dystrophy (DMD) in the US, increasing Share XNS Pharma steals a march on Sarepta with DMD drughttps://pharmaphorum.com/news/ns-pharma-steals-a-march-on-sarepta-with-dmd-drug/
Industry’s first dedicated Neuromuscular Drug Development (NMD) SummitNMD Summit Share XIndustry’s first dedicated Neuromuscular Drug Development (NMD) Summithttps://pharmaphorum.com/events/industrys-first-dedicated-neuromuscular-drug-development-nmd-summit/
